The European Commission opened a public consultation on July 8, 2026, on commitments offered by Sanofi to settle competition concerns tied to a campaign the company ran against a rival flu vaccine.
The Commission, acting from Brussels, alleges that Sanofi's communication campaign disparaged a competing vaccine. That rival product is the only flu vaccine recommended for vulnerable patients who carry specific risk factors, making the alleged conduct a matter of particular concern for regulators.
The Commission said Sanofi's campaign may have constituted anticompetitive behavior. By inviting public feedback on the proposed commitments, the Commission is following a standard procedure that allows third parties to weigh in before any formal resolution is reached.
The consultation centers on whether Sanofi's offered commitments adequately address the harm the Commission identified. The affected group, vulnerable individuals with risk factors, depends on the targeted vaccine as their sole recommended option for flu protection, according to the Commission's press release issued on July 8, 2026.